BioLight Life Sciences Balance Sheet Health
Financial Health criteria checks 6/6
BioLight Life Sciences has a total shareholder equity of ₪31.4M and total debt of ₪0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ₪35.8M and ₪4.4M respectively.
Key information
0%
Debt to equity ratio
₪0
Debt
| Interest coverage ratio | n/a |
| Cash | ₪13.42m |
| Equity | ₪31.38m |
| Total liabilities | ₪4.40m |
| Total assets | ₪35.79m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: BOLT's short term assets (₪14.1M) exceed its short term liabilities (₪3.2M).
Long Term Liabilities: BOLT's short term assets (₪14.1M) exceed its long term liabilities (₪1.2M).
Debt to Equity History and Analysis
Debt Level: BOLT is debt free.
Reducing Debt: BOLT had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BOLT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: BOLT has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 16.6% each year.